Lomustine

As palliative or supplementary treatment, usually in combination with radiotherapy and/or surgery as part of multiple drug regimens in: - brain tumours (primary or metastatic) - lung tumours (especially oat-cell carcinoma) Hodgkin’s disease (resistant to conventional combination chemotherapy) - malignant melanoma (metastatic) Lomustine "medac" may also be of value as second-line treatment in Non-Hodgkin's lymphoma, myelomatosis, gastrointestinal tumours, carcinoma of the kidney, the testis, the ovary, the cervix uteri and the breast.

AND CLINICAL USES

CeeNU (lomustine-CCNU) is indicated as palliative therapy in addition to surgery and radiotherapy or in combination therapy with other chemotherapeutic agents in the following: 1. Brain tumors - both primary and metastatic, in patients who have already received appropriate surgical and/or radiotherapeutic procedures.

2. Hodgkin's Disease – as a secondary therapy, alone or in combination with other active drugs. Other Tumors – CeeNU has been used in combination with other therapeutic agents in lung cancer (squamous cell, anaplastic large cell, and adenocarcinoma), malignant melanoma and breast cancer (advanced disease) only after other conventional methods have failed.

CONTRAINDICATIONS CeeNU (lomustine-CCNU) should not be given to individuals who have demonstrated a previous hypersensitivity to it. Also it is contraindicated in patients having severe leukopenia and/or thrombocytopenia. WARNINGS CeeNU (lomustine-CCNU) should be administered by individuals experienced in the use of antineoplastic therapy.